FLT4 | Fms-related tyrosine kinase 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| ![](/images_static/rna_center.gif) | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Mixed |
FOLH1 | Folate hydrolase (prostate-specific membrane antigen) 1 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images/1451/ihc_cell_selected_60x60.jpg) | ![](/images/1451/4356_B_1_4_rna_selected_60x60.jpg) | Tissue enhanced |
GABBR2 | Gamma-aminobutyric acid (GABA) B receptor, 2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/13820/142579_B_8_2_rna_selected_60x60.jpg) | Tissue enriched |
GABRA1 | Gamma-aminobutyric acid (GABA) A receptor, alpha 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images/55746/ihc_cell_selected_60x60.jpg) | ![](/images/22502/106616_B_8_1_rna_selected_60x60.jpg) | Tissue enriched |
GABRD | Gamma-aminobutyric acid (GABA) A receptor, delta | Disease related genes FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/44371/151898_B_8_7_rna_selected_60x60.jpg) | Tissue enriched |
GGCX | Gamma-glutamyl carboxylase | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/18284/42500_B_9_1_rna_selected_60x60.jpg) | Expressed in all |
GLP2R | Glucagon-like peptide 2 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/49244/122475_B_7_7_rna_selected_60x60.jpg) | Tissue enhanced |
GLRA2 | Glycine receptor, alpha 2 | FDA approved drug targets Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images/53525/ihc_cell_selected_60x60.jpg) | ![](/images/53525/135622_A_2_5_rna_selected_60x60.jpg) | Group enriched |
GRIA1 | Glutamate receptor, ionotropic, AMPA 1 | FDA approved drug targets Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images/35202/ihc_cell_selected_60x60.jpg) | ![](/images/35202/135516_A_2_1_rna_selected_60x60.jpg) | Tissue enriched |
GRIN2A | Glutamate receptor, ionotropic, N-methyl D-aspartate 2A | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/22725/151909_B_7_4_rna_selected_60x60.jpg) | Tissue enhanced |
HDAC6 | Histone deacetylase 6 | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | ![](/images/3714/ihc_cell_selected_60x60.jpg) | ![](/images/26321/57610_A_3_2_rna_selected_60x60.jpg) | Expressed in all |
HMGCR | 3-hydroxy-3-methylglutaryl-CoA reductase | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images/8338/ihc_cell_selected_60x60.jpg) | ![](/images/8338/23048_A_6_1_rna_selected_60x60.jpg) | Expressed in all |
HRH1 | Histamine receptor H1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| ![](/images/29740/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/29740/63005_B_9_5_rna_selected_60x60.jpg) | Mixed |
HSD3B1 | Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 | Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/43261/103681_B_8_1_rna_selected_60x60.jpg) | Tissue enriched |
HSD3B2 | Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/43261/103681_B_8_1_rna_selected_60x60.jpg) | Tissue enriched |
HTR2A | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/14011/142185_B_8_1_rna_selected_60x60.jpg) | Tissue enriched |
HTR2B | 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/12867/31386_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
HTR7 | 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins RAS pathway related proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/22708/53493_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
ICAM1 | Intercellular adhesion molecule 1 | Cancer-related genes Candidate cardiovascular disease genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images/2142/if_selected_60x60.jpg) | | ![](/images/2142/5934_B_7_3_rna_selected_60x60.jpg) | Expressed in all |
IL2RA | Interleukin 2 receptor, alpha | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images/2419/ihc_cell_selected_60x60.jpg) | ![](/images/2419/6368_B_7_3_rna_selected_60x60.jpg) | Tissue enhanced |
IL2RB | Interleukin 2 receptor, beta | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/62657/139409_B_8_4_rna_selected_60x60.jpg) | Tissue enhanced |
IL2RG | Interleukin 2 receptor, gamma | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/46641/107861_B_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
INSR | Insulin receptor | CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| ![](/images/36302/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/36302/112004_B_9_2_rna_selected_60x60.jpg) | Expressed in all |
ITGA2B | Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/31168/73887_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
ITGAL | Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/25011/57822_B_8_1_rna_selected_60x60.jpg) | Expressed in all |
ITGAV | Integrin, alpha V | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins
| | ![](/images/4856/if_selected_60x60.jpg) | | ![](/images/4856/13045_B_8_6_rna_selected_60x60.jpg) | Expressed in all |
ITGB1 | Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | ![](/images/3434/9046_B_7_8_rna_selected_60x60.jpg) | Expressed in all |
KCNA10 | Potassium voltage-gated channel, shaker-related subfamily, member 10 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | ![](/images/22564/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/15061/34147_B_7_3_rna_selected_60x60.jpg) | Not detected |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/21516/109609_B_7_2_rna_selected_60x60.jpg) | Group enriched |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/42434/134323_B_1_7_rna_selected_60x60.jpg) | Tissue enhanced |
KCNC1 | Potassium voltage-gated channel, Shaw-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images/47634/ihc_cell_selected_60x60.jpg) | ![](/images/47634/111871_B_8_5_rna_selected_60x60.jpg) | Tissue enriched |
KCNC2 | Potassium voltage-gated channel, Shaw-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| ![](/images/22571/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/19664/45838_B_9_2_rna_selected_60x60.jpg) | Tissue enriched |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/18656/42007_B_1_3_rna_selected_60x60.jpg) | Tissue enhanced |
KCNQ2 | Potassium voltage-gated channel, KQT-like subfamily, member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images/57112/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/57112/140451_B_8_1_rna_selected_60x60.jpg) | Group enriched |
KDR | Kinase insert domain receptor (a type III receptor tyrosine kinase) | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | ![](/images/30893/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/4028/11466_B_8_5_rna_selected_60x60.jpg) | Mixed |
KIT | V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | ![](/images_static/na_center.gif) | | ![](/images/3288/8263_A_3_6_rna_selected_60x60.jpg) | Mixed |
LHCGR | Luteinizing hormone/choriogonadotropin receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images/9814/ihc_cell_selected_60x60.jpg) | ![](/images/9814/31107_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
MAOA | Monoamine oxidase A | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/9437/30396_B_9_2_rna_selected_60x60.jpg) | Mixed |
MAOB | Monoamine oxidase B | Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | ![](/images/2328/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/2328/7274_B_9_4_rna_selected_60x60.jpg) | Mixed |
MET | Met proto-oncogene | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| ![](/images/5282/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/5282/15801_A_8_1_rna_selected_60x60.jpg) | Mixed |
MGAM | Maltase-glucoamylase (alpha-glucosidase) | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/2270/8419_B_8_5_rna_selected_60x60.jpg) | Group enriched |
MME | Membrane metallo-endopeptidase | Cancer-related genes Candidate cardiovascular disease genes CD markers Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/13/117_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
MMP15 | Matrix metallopeptidase 15 (membrane-inserted) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| ![](/images/40390/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/40390/92316_A_3_6_rna_selected_60x60.jpg) | Mixed |
MPL | Myeloproliferative leukemia virus oncogene | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| ![](/images/7619/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/7619/29018_B_2_8_rna_selected_60x60.jpg) | Not detected |
MS4A1 | Membrane-spanning 4-domains, subfamily A, member 1 | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | | ![](/images/14341/39080_B_8_5_rna_selected_60x60.jpg) | Group enriched |
MS4A2 | Membrane-spanning 4-domains, subfamily A, member 2 | FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images/59967/ihc_cell_selected_60x60.jpg) | ![](/images/59967/135063_B_7_2_rna_selected_60x60.jpg) | Mixed |
OPRM1 | Opioid receptor, mu 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images/14509/ihc_cell_selected_60x60.jpg) | ![](/images/14509/34609_B_4_5_rna_selected_60x60.jpg) | Group enriched |
P2RY12 | Purinergic receptor P2Y, G-protein coupled, 12 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/14518/33943_B_8_2_rna_selected_60x60.jpg) | Tissue enriched |
PDE3A | Phosphodiesterase 3A, cGMP-inhibited | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| ![](/images/14492/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/14492/34301_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
PDGFRB | Platelet-derived growth factor receptor, beta polypeptide | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | ![](/images/28499/if_selected_60x60.jpg) | | ![](/images/3842/10176_B_9_3_rna_selected_60x60.jpg) | Mixed |